Showing results (1-10 of 335) with videos related to
Sort By:
Pageof 34
Blood|September 15, 2021
Defining and treating high-grade B-cell lymphoma, NOSAdam J Olszewski, Habibe Kurt, Andrew M EvensLeukemia & Lymphoma|September 1, 2021
CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximabAndrew Hsu, Habibe Kurt, Adam S Zayac, et al.Current Opinion in Oncology|January 1, 2005
Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancerAndrew M EvensHematological Oncology|June 15, 2025
Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic EraAndrew M EvensClinical Lymphoma, Myeloma & Leukemia|November 12, 2025
SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell LymphomasAdam J OlszewskiAmerican Journal of Hematology|August 14, 2012
Survival outcomes with and without splenectomy in splenic marginal zone lymphomaAdam J OlszewskiBlood|November 28, 2014
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAndrew M Evens, Lale KostakogluHematology. American Society of Hematology. Education Program|February 20, 2015
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAndrew M Evens, Lale KostakogluCurrent Opinion in Oncology|May 25, 2006
Targeting angiogenesis for the treatment of sarcomaLakshmi Balasubramanian, Andrew M EvensClinical Advances in Hematology & Oncology : H&O|July 8, 2014
FDG-PET imaging for Hodgkin lymphoma: current use and future applicationsLale Kostakoglu, Andrew M EvensPageof 34